J. Vergallo, Eric Karran (Cambridge), Manuela Graziani (Roma), Marion Haberkamp

P. N. Alexandrov, P. Dua, J. M. Hill, S. Bhattacharjee, Y. Zhao et al., MicroRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF), Int. J. Biochem. Mol. Biol, vol.3, pp.365-373, 2012.

D. Athauda, S. Gulyani, H. Karnati, Y. Li, D. Tweedie et al., Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the exenatide-pd trial, JAMA Neurol, 2019.

P. Bergman, E. Piket, M. Khademi, T. James, L. Brundin et al., Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis, Neurol. Neuroimmunol. Neuroinflamm, vol.3, p.219, 2016.

J. L. Cummings, Biomarkers in Alzheimer's disease drug development, Alzheimers Dement, vol.7, 2011.

X. Deng and Y. Nakamura, Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy, Trends Pharmacol. Sci, vol.38, pp.15-24, 2017.

A. Drilon, T. W. Laetsch, S. Kummar, S. G. Dubois, U. N. Lassen et al., Efficacy of larotrectinib in trk fusion-positive cancers in adults and children, N. Engl. J. Med, vol.378, pp.731-739, 2018.

D. B. Dubal and S. J. Pleasure, Neural-derived extracellular vesicles in clinical trials: message in a bottle, JAMA Neurol, 2019.

E. Eitan, V. Tosti, C. N. Suire, E. Cava, S. Berkowitz et al., In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles, Aging Cell, vol.16, pp.1430-1433, 2017.

N. Fandos, V. Perez-grijalba, P. Pesini, S. Olmos, M. Bossa et al., Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals, pp.179-187, 2017.

M. T. Ferretti, M. F. Iulita, E. Cavedo, P. A. Chiesa, A. Schumacher-dimech et al., Sex differences in Alzheimer diseasethe gateway to precision medicine, Nat. Rev. Neurol, vol.14, pp.457-469, 2018.

M. S. Fiandaca, D. Kapogiannis, M. Mapstone, A. Boxer, E. Eitan et al., Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study, Alzheimers Dement, vol.11, pp.600-607, 2015.

H. Geerts, R. Gieschke, and R. Peck, Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases, Expert Rev. Clin. Pharmacol, vol.11, pp.789-795, 2018.

H. Geerts, P. Roberts, S. , and A. , Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology, Front. Pharmacol, vol.6, p.198, 2015.

G. Gibson, Going to the negative: genomics for optimized medical prescription, Nat. Rev. Genet, vol.20, pp.1-2, 2019.

E. J. Goetzl, M. Mustapic, D. Kapogiannis, E. Eitan, I. V. Lobach et al., Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease, FASEB J, vol.30, pp.3853-3859, 2016.

E. J. Goetzl, J. B. Schwartz, M. Mustapic, I. V. Lobach, R. Daneman et al., Altered cargo proteins of human plasma endothelial cell-derived exosomes in atherosclerotic cerebrovascular disease, FASEB J, vol.31, pp.3689-3694, 2017.

E. J. Goetzl, E. L. Abner, G. A. Jicha, D. Kapogiannis, and J. B. Schwartz, Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease, FASEB J, vol.32, pp.888-893, 2018.

E. J. Goetzl, J. B. Schwartz, E. L. Abner, G. A. Jicha, and D. Kapogiannis, High complement levels in astrocyte-derived exosomes of Alzheimer disease, Ann. Neurol, vol.83, pp.544-552, 2018.

K. B. Goldberg, G. M. Blumenthal, A. E. Mckee, and R. Pazdur, The FDA oncology center of excellence and precision medicine, Exp. Biol. Med, vol.243, pp.308-312, 2018.

H. Hampel, S. E. O'bryant, J. L. Molinuevo, H. Zetterberg, C. L. Masters et al., Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic, Nat. Rev. Neurol, vol.14, pp.639-652, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01972372

H. Hampel, N. Toschi, C. Babiloni, F. Baldacci, K. L. Black et al., Revolution of alzheimer precision neurology. passageway of systems biology and neurophysiology, J. Alzheimers. Dis, vol.64, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01910402

H. Hampel, N. Toschi, F. Baldacci, H. Zetterberg, K. Blennow et al., Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: abeta1-42, totaltau, phosphorylated-tau, NFL, neurogranin, and YKL-40, Alzheimers Dement, vol.14, pp.492-501, 2018.

H. Hampel, A. Vergallo, L. F. Aguilar, N. Benda, K. Broich et al., Precision pharmacology for Alzheimer's disease, Pharmacol. Res, vol.130, pp.331-365, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02095292

E. Heitzer, I. S. Haque, C. E. Roberts, and M. R. Speicher, Current and future perspectives of liquid biopsies in genomics-driven oncology, Nat. Rev. Genet, vol.20, pp.71-88, 2019.

C. R. Jack, D. A. Bennett, K. Blennow, M. C. Carrillo, H. H. Feldman et al., A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-547, 2016.

J. T. Jorgensen and M. Hersom, Companion diagnostics-a tool to improve pharmacotherapy, Ann. Transl. Med, vol.4, p.482, 2016.

D. Kozakov, D. R. Hall, R. L. Napoleon, C. Yueh, A. Whitty et al., New frontiers in druggability, J. Med. Chem, vol.58, pp.9063-9088, 2015.

H. Kvartsberg, F. H. Duits, M. Ingelsson, N. Andreasen, A. Ohrfelt et al., Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease, Alzheimers Dement, vol.11, pp.1180-1190, 2015.

N. Mattsson, U. Andreasson, H. Zetterberg, and K. Blennow, Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease, JAMA Neurol, vol.74, pp.557-566, 2017.

M. M. Mielke, C. E. Hagen, J. Xu, X. Chai, P. Vemuri et al., Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography, Alzheimers Dement, vol.14, pp.989-997, 2018.

C. Mitsopoulos, A. C. Schierz, P. Workman, A. , and B. , Distinctive behaviors of druggable proteins in cellular networks, PLoS Comput. Biol, vol.11, 2015.

J. L. Molinuevo, S. Ayton, R. Batrla, M. M. Bednar, T. Bittner et al., Current state of Alzheimer's fluid biomarkers, Acta Neuropathol, vol.136, pp.821-853, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01960281

M. Mustapic, E. Eitan, J. K. Werner, S. T. Berkowitz, M. P. Lazaropoulos et al., Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes, Front. Neurosci, vol.11, p.278, 2017.

A. Nakamura, N. Kaneko, V. L. Villemagne, T. Kato, J. Doecke et al., High performance plasma amyloid-beta biomarkers for Alzheimer's disease, Nature, vol.554, pp.249-254, 2018.

K. Nho, J. J. Corneveaux, S. Kim, H. Lin, S. L. Risacher et al., Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment, Mol. Psychiatry, vol.18, pp.781-787, 2013.

N. C. Nicolaides, D. J. O'shannessy, E. Albone, and L. Grasso, Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy, Front. Oncol, vol.4, p.141, 2014.

S. E. O'bryant, M. M. Mielke, R. A. Rissman, S. Lista, H. Vanderstichele et al., Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic, Alzheimers Dement, vol.13, pp.45-58, 2017.

K. Pantel, A. , and C. , Liquid biopsy and minimal residual disease -latest advances and implications for cure, Nat. Rev. Clin. Oncol, 2019.

J. C. Park, S. Han, D. Yi, M. S. Byun, J. H. Lee et al., Plasma tau/amyloid-beta1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease, Brain, vol.142, pp.771-786, 2019.

A. A. Pimenova, T. Raj, and A. M. Goate, Untangling genetic risk for Alzheimer's Disease, Biol. Psychiatry, vol.83, pp.300-310, 2018.

O. Preische, S. A. Schultz, A. Apel, J. Kuhle, S. A. Kaeser et al., Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease, Nat. Med, vol.25, pp.277-283, 2019.

L. Pulliam, B. Sun, M. Mustapic, S. Chawla, and D. Kapogiannis, Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease, J. Neurovirol, 2019.

M. Rask-andersen, S. Masuram, and H. B. Schioth, The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication, Annu. Rev. Pharmacol. Toxicol, vol.54, pp.9-26, 2014.

P. Roberts, A. Spiros, and H. Geerts, A humanized clinically calibrated quantitative systems pharmacology model for hypokinetic motor symptoms in parkinson's disease, Front. Pharmacol, vol.7, p.6, 2016.

D. H. Roukos, Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine, Drug Discov. Today, vol.22, pp.1148-1164, 2017.

S. Schubbert, G. Bollag, N. Lyubynska, H. Nguyen, C. P. Kratz et al., Biochemical and functional characterization of germ line KRAS mutations, Mol. Cell. Biol, vol.27, pp.7765-7770, 2007.

Y. Shen, H. Wang, Q. Sun, H. Yao, A. P. Keegan et al., increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment, Biol. Psychiatry, vol.83, pp.447-455, 2018.

H. M. Snyder, M. C. Carrillo, F. Grodstein, K. Henriksen, A. Jeromin et al., Developing novel blood-based biomarkers for Alzheimer's disease, Alzheimers Dement, vol.10, pp.109-114, 2014.

S. S. Sorensen, A. B. Nygaard, and T. Christensen, MiRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia -an exploratory study, Transl. Neurodegener, vol.5, p.6, 2016.

J. D. Twomey, N. N. Brahme, and B. Zhang, Drug-biomarker codevelopment in oncology -20 years and counting, Drug Resist. Updat, vol.30, pp.48-62, 2017.

A. Vergallo, R. Bun, N. Toschi, F. Baldacci, H. Zetterberg et al., Association of cerebrospinal fluid alpha-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers, Alzheimers Dement, vol.14, pp.1623-1631, 2018.

J. C. Wan, C. Massie, J. Garcia-corbacho, F. Mouliere, J. D. Brenton et al., Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nat. Rev. Cancer, vol.17, pp.223-238, 2017.

F. Wu, C. Ma, and C. Tan, Network motifs modulate druggability of cellular targets, Sci. Rep, vol.6, p.36626, 2016.

Y. Zhao, P. N. Alexandrov, and W. J. Lukiw, Anti-microRNAs as novel therapeutic agents in the clinical management of Alzheimer's Disease, Front. Neurosci, vol.10, p.59, 2016.

E. Axovant, C. Lilly, . Ltd, . Ge-healthcare, . Takeda et al., He is co-inventor in the following patents as a scientific expert and has received no royalties: ? In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388. ? In, Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784. Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300. ? In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463. ? In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286. ? In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822. ? In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number: 7547553. CSF Diagnostic in vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797. ? In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number

, ? Neurodegenerative Markers for Psychiatric Conditions Publication